Is it true or not about BCRX?# Stock
b*7
1 楼
http://seekingalpha.com/article/182425-biocryst-peramivir-approval-opens-japanese-market
BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
Shionogi & Co., has been granted approval for peramivir in Japan, triggering
the third $7 million clinical development milestone payment from Shionogi
to BioCryst. BioCryst will receive an additional $95 million as commercial
milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
on Shionogi's sales, and will capture
BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
Shionogi & Co., has been granted approval for peramivir in Japan, triggering
the third $7 million clinical development milestone payment from Shionogi
to BioCryst. BioCryst will receive an additional $95 million as commercial
milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
on Shionogi's sales, and will capture